Ironwood Pharmaceuticals reported $583.99M in Debt for its fiscal quarter ending in December of 2024.





Debt Change Date
Acadia Pharmaceuticals USD 73.85M 23.06M Jun/2026
Agios Pharmaceuticals USD 31.17M 4.57M Jun/2026
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
Almirall EUR 356.11M 13.25M Jun/2026
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
Amarin USD 0 0 Mar/2025
Ardelyx USD 256.19M 47.93M Jun/2026
Astellas Pharma JPY 589.87B 23.92B Jun/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
Charles River Laboratories USD 3.03B 28.55M Jun/2026
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Emergent BioSolutions USD 903.2M 495.2M Jun/2023
Halozyme Therapeutics USD 2.15B 2.02M Jun/2026
Incyte USD 38.27M 1.16M Jun/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Lexicon Pharmaceuticals USD 99.51M 243K Dec/2023
MacroGenics USD 35.09M 1.42M Jun/2026
Moderna USD 1.29B 11M Jun/2026
Myriad Genetics USD 59.3M 19.7M Mar/2025
Pacira USD 293.59M 69.53M Sep/2026
PTC Therapeutics USD 2.84B 2.15B Sep/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Sarepta Therapeutics USD 857.36M 188.48M Sep/2026
Takeda JPY 4.58T 364.32B Sep/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024